A phase 1 multi-centre, randomized, single-blind, steady-state study to evaluate pharmacokinetics, pharmacodynamics, safety and tolerability after multiple-dose administration of three different doses of naronapride in patients with moderate idiopathic or diabetic gastroparesis compared to healthy subjects

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516197-30-00

Acronym

NAT-022/BIO

Enrollment

Registered

2025-04-25

Start date

2025-07-16

Completion date

Unknown

Last updated

2025-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic or diabetic gastroparesis

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, Germany, Poland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026